Overview
Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.
Current Appointments & Affiliations
James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
·
2023 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics
·
2012 - Present
Biostatistics & Bioinformatics, Division of Biostatistics,
Biostatistics & Bioinformatics
Chief, Division of Biostatistics
·
2019 - Present
Biostatistics & Bioinformatics,
Basic Science Departments
Member of the Duke Cancer Institute
·
1996 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP).
Journal Article Ann Oncol · December 31, 2025 BACKGROUND: Large language models (LLMs) are rapidly being integrated into healthcare, with substantial implications for oncology practice. The European Society for Medical Oncology (ESMO) developed the ESMO guidance on the use of Large Language Models in ... Full text Link to item CiteNational Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.
Journal Article J Clin Oncol · October 23, 2025 PURPOSE: Biochemical recurrence (BCR) of prostate cancer (PCa) after definitive surgery and/or radiation (including salvage strategies) is a burgeoning area of clinical research inspired by ultrasensitive next-generation imaging. Most phase III trials in P ... Full text Link to item CiteOlaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Journal Article JCO Precis Oncol · October 2025 PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of targeted agents in patients with advanced cancer and genomic alterations. Results of five cohorts of patients with BRCA1/2- ... Full text Link to item CiteRecent Grants
The COVID-19 and Cancer Consortium (CCC19) Registry
ResearchPrincipal Investigator · Awarded by Rhode Island Hospital · 2024 - 2029Assessing Prognoses and Validating Surrogate Endpoints for Clinical Outcomes in Metastatic Hormone Sensitive Prostate Cancer
ResearchPrincipal Investigator · Awarded by Department of Defense · 2025 - 2028Research Triangle Center of Excellence in Regulatory Science and Innovation (CERSI)
ResearchCo Investigator · Awarded by University of North Carolina - Chapel Hill · 2023 - 2028View All Grants
Education, Training & Certifications
University of Texas Health Sciences Center, Houston ·
1994
Ph.D.